Advanced squamous cell carcinoma of the oropharynx: efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy.
Head Neck., Apr;31(4):452-60 (2009)
Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma.
Cancer., Apr;71(7):2326-31 (1993)
Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.
J. Clin. Oncol., May;12(5):946-53 (1994)
Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma.
Cancer., Nov;98(10):2177-83 (2003)
Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.
Invest New Drugs., Jan;22(1):91-7 (2004)
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Cancer., Jul;107(2):319-27 (2006)
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.
J. Clin. Oncol., Jul;26(19):3128-37 (2008)
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
J. Clin. Oncol., Jul;26(19):3138-46 (2008)
Chemotherapy alone for organ preservation in advanced laryngeal cancer.
Head Neck., Aug;32(8):1040-7 (2010)
Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer.
Int. J. Radiat. Oncol. Biol. Phys., Dec;63(5):1395-9 (2005)
Preoperative chemoradiation for the treatment of locoregional esophageal cancer: the standard of care?
Semin Radiat Oncol., Jan;17(1):45-52 (2007)
Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
Int. J. Radiat. Oncol. Biol. Phys., 69(2 Suppl):S106-8 (2007)
Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking.
Int. J. Radiat. Oncol. Biol. Phys., 69(2 Suppl):S109-11 (2007)